The role of salvage treatment in advanced colorectal cancer.

[1]  C. Punt,et al.  Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) , 2008 .

[2]  E. Van Cutsem,et al.  KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Mocellin,et al.  Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Kemeny,et al.  Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Dongsheng Tu,et al.  Cetuximab for the treatment of colorectal cancer. , 2007, The New England journal of medicine.

[7]  M. Ducreux,et al.  Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Gonen,et al.  Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Y. Bang,et al.  3012 ORAL Capecitabine + oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase III trial results , 2007 .

[10]  W. Scheithauer,et al.  3003 ORAL Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial , 2007 .

[11]  Richard J Stephens,et al.  Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial , 2007, The Lancet.

[12]  Linda Mol,et al.  Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial , 2007, The Lancet.

[13]  W. Scheithauer,et al.  UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer – a retrospective analysis , 2007, Anti-cancer drugs.

[14]  P. Jänne,et al.  EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer , 2007 .

[15]  M. Hebbar,et al.  Antitumour activity of pemetrexed (Pem) and irinotecan (Iri) in second-line metastatic colorectal cancer (MCRC) patients: A multicenter phase II study , 2007 .

[16]  V. Michalaki,et al.  Mitomycin-C and capecitabine as salvage chemotherapy in pre-treated patients with advanced colorectal cancer , 2007 .

[17]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  T. Frebourg,et al.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.

[20]  Silvia Benvenuti,et al.  Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.

[21]  Josep Tabernero,et al.  The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents , 2007, Molecular Cancer Research.

[22]  E. Van Cutsem,et al.  Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Grochow,et al.  Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  F. Lévi,et al.  Effective salvage therapy of liver-only colorectal cancer metastases with chronomodulated irinotecan-fluorouracil-oxaliplatin via hepatic artery infusion. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Aapro,et al.  MABEL-A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  K. Syrigos,et al.  Multicenter Phase II Study of Gemcitabine and Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Colorectal Cancer Patients Pretreated with 5-Fluorouracil plus Irinotecan , 2006, Oncology.

[27]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[28]  G. Pond,et al.  Clinical studies. , 2000, Women alive.

[29]  Jeffrey W. Clark,et al.  Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. LaFleur,et al.  Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Advani,et al.  Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Agnès Laplanche,et al.  Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  E. Vokes,et al.  Phase I/II Trial of Gefitinib and Oxaliplatin in Patients With Advanced Colorectal Cancer , 2005, American journal of clinical oncology.

[34]  L. Schwartz,et al.  Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Sargent,et al.  N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU , 2005 .

[36]  S. Kubicka,et al.  Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial , 2005 .

[37]  D. Sargent,et al.  Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy , 2005 .

[38]  P. Catalano,et al.  High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 , 2005 .

[39]  L. Seymour,et al.  A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer , 2005, Investigational New Drugs.

[40]  Joon-Oh Park,et al.  Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study , 2005, Cancer Chemotherapy and Pharmacology.

[41]  F. Lévi,et al.  Tumor Progression While on Chemotherapy: A Contraindication to Liver Resection for Multiple Colorectal Metastases? , 2004, Annals of surgery.

[42]  Bernard Paule,et al.  Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.

[43]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[44]  P. Beale,et al.  A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients , 2004 .

[45]  H. Sorbye,et al.  Phase II study of short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) in patients with progressive colorectal cancer after irinotecan and 5-fluorouracil (FU) treatment , 2004 .

[46]  J. García-Foncillas,et al.  Irinotecan and mitomycin C (MMC) as salvage therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, irinotecan and/or oxaliplatin based chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  S. Monfardini,et al.  Gemcitabine (GEM) as salvage therapy in patients (pts) with advanced colorectal cancer (CRC) refractory to 5-fluorouracil (FU), irinotecan (IRI) and oxaliplatin (OXA). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  F. Lévi,et al.  Chronomodulated irinotecan (I), fluorouracil (F), leucovorin (L), and oxaliplatin (O) (chrono IFLO) as salvage therapy in oxaliplatin- and irinotecan-resistant advanced colorectal cancer (ACRC): Treatment results and toxicity profile. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Rothenberg.  Current Approaches to First-Line Treatment of Advanced Colorectal Cancer , 2004 .

[50]  M. Rothenberg.  Current status of second-line therapy for metastatic colorectal cancer. , 2004, Clinical colorectal cancer.

[51]  E. Chu.  Bevacizumab targeted therapy: validation of angiogenesis as a key target for advanced colorectal cancer. , 2004, Clinical colorectal cancer.

[52]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  D. Sargent,et al.  Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  J. Berlin,et al.  Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  A. Rossi,et al.  Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. , 2003, Anticancer research.

[58]  W. Jarnagin,et al.  Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases , 2003, Journal of Gastrointestinal Surgery.

[59]  M. Ducreux,et al.  Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  G. Fontanini,et al.  Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  J. Lotz,et al.  Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. , 1999, European journal of cancer.

[62]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[63]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[64]  H. Ludwig,et al.  The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer , 1993, Cancer.